Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YL 202

Next Previous
X
Search
Drug Profile

YL 202

Alternative Names: BNT-326; YL-202

Latest Information Update: 28 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MediLink Therapeutics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HER2 negative breast cancer; Solid tumours
  • Phase I Non-small cell lung cancer

Most Recent Events

  • 25 Sep 2024 MediLink Therapeutics re-initiates a phase I trial in HER2-negative-breast-cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) and Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater)in China and USA (IV) (NCT05653752)
  • 17 Jun 2024 US FDA places partial clinical hold on a phase I trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and China (IV) (NCT05653752)
  • 03 Jun 2024 MediLink Therapeutics plans a phase II trial for Breast cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable) in China (IV, Infusion) (NCT06439771)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top